MedTrace Logo

Gut Microbiota, the Potential Key to Modulating Humoral Immunogenicity of New Platform COVID-19 Vaccines

NCT05150834 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 53

Last updated 2021-12-09

No results posted yet for this study

Summary

Vaccination is the best way to mitigate the coronavirus disease 2019 (COVID-19) pandemic, but the vaccine immunogenicity may be quite variable from person to person. There is increasing evidence suggesting that the gut microbiome is a major determinant of vaccine immunogenicity. Thus, the investigators investigated the relationship between gut microbiota and humoral immune response after COVID-19 vaccination.

Conditions

Interventions

OTHER

This is observational study

We enrolled the healthcare workers assigned to get either BNT162b2 or ChAdOx1 by the Korean government.

Sponsors & Collaborators

  • Korea University Guro Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-25
Primary Completion
2021-07-16
Completion
2023-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05150834 on ClinicalTrials.gov